PCSK9 and hepatocellular carcinoma: Liraglutide, a once-daily glucagon-like peptide-1 (GLP-1) agonist, was found to suppress PCSK9 expression via a hepatocyte nuclear factor 1 alpha (HNF1α)-dependent mechanism in the human hepatoma cell line, HepG2 [20].